Related Experiment Videos
Olmesartan, an AT1-selective antihypertensive agent.
Kim Chilman-Blair1, Xavier Rabasseda
1Medical Information Department, Prous Science, Barcelona, Spain.
Drugs of Today (Barcelona, Spain : 1998)
|December 12, 2003
Summary
Olmesartan, an angiotensin II receptor antagonist, effectively treats hypertension and offers organ protection beyond blood pressure reduction. Its superior efficacy and favorable tolerability make it a promising first-line option for essential hypertension.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Essential hypertension is a prevalent condition driven by the renin-angiotensin system.
- Angiotensin II causes vasoconstriction, increasing blood pressure.
- Diabetic nephropathy and cardiovascular events are significant complications.
Purpose of the Study:
- To evaluate olmesartan as a treatment for essential hypertension.
- To investigate olmesartan's organ-protective effects.
- To compare olmesartan's efficacy and tolerability to existing antihypertensive agents.
Main Methods:
- Olmesartan selectively blocks angiotensin II type 1 (AT(1)) receptors.
- Studies assessed blood pressure lowering properties.
- End-organ protection mechanisms were investigated.
Main Results:
- Olmesartan demonstrates superior efficacy compared to other antihypertensives.
- Tolerability is comparable to placebo.
- Organ protection effects are independent of blood pressure reduction.
Conclusions:
- Olmesartan is a highly effective and well-tolerated treatment for essential hypertension.
- Its once-daily dosing offers convenience for patients.
- Olmesartan is a promising first-line therapy for mild to severe hypertension.